Revelation Biosciences, Inc.
REVB
Last
$0.76
Day
-2.6%
1y
-86.8%
5y
-100.0%
52w
-87.6%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-0526d
EMA 21
0.86
EMA 50
0.94
EMA 200
31.58
20d high
-24.1%
5y high
-100.0%
5y range
0th
Positions held
Your positionsREVB isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-30
Hold
avoid
Signal
Strong Sell
Target
$0.88
Stop
$0.69
Stop distance
9.2%
Target vs last
+15.8%
Fundamentals
| Market cap | $3.08M | Enterprise value | -$7.66M | Trailing P/E | 0.17 | Forward P/E | -0.27 |
| PEG | — | Price / book | 0.30 | Beta | -0.06 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -1.5% | ROA | -78.7% | Debt / equity | 0.07 |
| Current ratio | 6.21 | Free cash flow | -$5.78M | Analyst recommendation | none | Mean target | $17.75 |
| 52w high | $6.24 | 52w low | $0.75 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$3.3M | -$3.0M | -$2.5M | -$1.9M | -$2.4M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$3.7M | -$3.1M | -$2.6M | -$1.9M | -$2.5M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$8.9M | -$15.0M | -$0.1M | -$10.8M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$9.1M | -$8.0M | -$8.7M | -$10.9M |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-08-19 · Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study
2026-08-07 · REVB Approaching a Critical Inflection Point
2026-08-06 · Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026
2026-07-21 · Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Price (daily)
Full chart · RSI · MACD · patternsREVB · daily-21.0% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin